CSL announced the exit of Paul McKenzie as chief executive. Senior executive Gordon Naylor appointed interim CEO. Shares of Australian biotech firm CSL plunged to an 8-year low Wednesday after it ...

With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the eve of its latest earnings announcement. Paul McKenzie, Ph.D., who’s served ...

CSL taps ex-vaccine division head Gordon Naylor as interim CEO Appointment of Naylor is a salvage mission, says analyst CSL shares close 5% lower; co to report HY results on Wed Feb 10 (Reuters) - ...

CSL Behring's Andembry can be used to prevent recurrent attacks of hereditary angioedema (HAE) by the NHS, according to finalised guidance from reimbursement authority NICE. The just-published ...

Bell Potter has given its take on this fallen giant. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to ...

A leading investment analyst believes CSL shares are trading at a steep discount. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become ...

It has been a good week for CSL Behring as it rolls out haemophilia B gene therapy Hemgenix, with positive reimbursement decisions in both the UK and Denmark. In the UK, health technology assessment ...

Chairman and former boss Brian McNamee has claimed the departing CEO didn’t have the skills to steer the global biotech’s future. The turmoil at the top adds to a horror six months for CSL. In that ...

Let's start with CSL's leadership change, because it sets the tone. Paul McKenzie has stepped down as chief executive, and the board has appointed long-time CSL executive and current director Gordon ...

The ASX 200 closed slightly lower, and the CSL chief executive stepped down abruptly ahead of tomorrow's half-year results. Catch up on the day's events and insights from our business reporters on the ...

Regulatory and policy issues in China and the US, which delivers 50% of revenues, have hit Australia’s largest listed biotech company's sales of vaccine and blood plasma products. Shares in ...

CSL shares slumped, dragging down the market, after the healthcare giant mis-timed the announcement of its chief executive’s departure, leaving investors furious. At 4.05pm, just minutes before the ...